School of Medicine  
Center for Diabetes Technology  
Safe
ty and Feasibility Testing of a  
Smaller Network Version of AIDANET 
Runn
ing Title: Smaller Network  Pi[INVESTIGATOR_2268] 
[STUDY_ID_REMOVED]  
Version Number: 
v1.[ADDRESS_192592]-2024   Page 3 of 60 
 
PROTOCOL VERSION HISTORY  
Version 
Number  Author(s)  Approver  Effective Date  Revision Description  
1.0 Sue Brown Sue Brown,  
Mark DeBoer  11-Sep-2024  Original Protocol  
1.1 Mary Oliveri  Sue Brown,  
Mark DeBoer  24-Sep-2024  FDA Modifications: 
• Modified Glycemi c 
Treatment Guidelines 
(section 7.6.1 ) 
• Modified Stoppi[INVESTIGATOR_134248] (section 12.9.1 ) 
1.2 Mark DeBoer  Sue Brown,  
Mark DeBoer  25-Sep-2024  FDA Modifications: 
• Modified Glycemi c 
Treatment Guidelines 
(section 7.6.1 ) 
 
1.[ADDRESS_192593]-2024  Study Team Modifications:  
• Added definition of 
AIDANET acronym  
(section 1.1) 
• Removed activity tracker 
(section 4.3) 
IRB Modifications : 
• Removed reference to assent 
(section 3.3) 
• Removed pregnancy test at 
hotel visit (section 7.3) 
 
  
CLINICAL PROTOCOL     
 
 
MiniNET _25-Oct-2024   Page 4 of 60 
 
SITE PRINCIPAL INVESTIGATOR [INVESTIGATOR_113411]:  Safety and Feasibility Testing of a Smaller Network Version of AIDANET  
Running Title:  Smaller Network  Pi[INVESTIGATOR_166028]/Date: v1.3/ 25-Oct-[ADDRESS_192594] read the protocol specified above.  In my formal capacity as a Site Principal Investigator, 
my duties include ensuring the safety of the study participants enrolled under my supervision.  It is understood that all information pertaining to the study will be held strictly confidential and that this confidentiality requirement applies to all study staff at this site.  
This trial will be carried out in accordance with ICH E6 Good Clinical Practice (GCP) and as required by [CONTACT_716]: [LOCATION_002] (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 812). 
As the Principal Investigator, I will assure that no deviation from, or changes to the protocol 
will take place without prior agreement from the sponsor and documented approval from the Institutional Review Board (IRB), or other approved Ethics Committee, except where necessary 
to eliminate an immediate hazard(s) to the trial participants.  
All key personnel (all individuals responsible for the design and conduct of this trial) have completed Human Participants Protection Training and Good Clinical Practice Training.  Further, I agree to ensure that all staff members involved in the conduct of this study are informed about 
their obligations in meeting the above commitments.  
 
Investigator’s Signature __________________________________Date: _____ / _____ / _____ Investigator’s Name: ________________________________ Site Name:  [CONTACT_166054] _25-Oct-[ADDRESS_192595] OF ABBREVIATIONS  
Abbreviation  Definition  
ADA  American Diabetes Association  
AE Adverse Event  
AID Automated insulin delivery  
AIDANET  Automated insulin delivery as Adaptive Network  
AP  Artificial pancreas  
AUC  Area Under the Curve  
AYA  Adolescent and Young Adult  
BDC  Barbara Davis Center  
BG Blood Glucose (as assessed by a blood glucose meter)  
BGM  Blood glucose meter  
CGM  Continuous glucose monitor  
CSII  Continuous subcutaneous insulin infusion  
DiAs  Diabetes Assistant  
DKA  Diabetic Ketoacidosis  
FCL Fully closed loop  
HbA1c  Hemoglobin A1c  
HCL  Hybrid closed loop  
JDRF  Juvenile Diabetes Research Foundation  
MDI  Multiple daily injections  
NAP  Neural network artificial pancreas  
SAE  Severe Adverse Event  
SG Sensor Glucose (as assessed by a continuous glucose monitor)  
SH Severe Hypoglycemia  
T1D Type 1 diabetes  
TAR  Time above range  
TBR  Time below range  
TIR Time in range 70 -180 mg/dL  
  
CLINICAL PROTOCOL     
 
 
MiniNET _25-Oct-2024   Page 6 of 60 
 
PROTOCOL SUMMARY  
Participant Area  Description  
Title  Safety and Feasibility Testing of a Smaller Network Version of AIDANET  
Investigational 
Device AIDANET algorithm as smaller network version with DiAs phone, Tandem t:AP insulin pumps, and Dexcom CGM  
Objectives  The primary objective of the project is to demonstrate feasibility and safety of the 
Automated Insulin Delivery as Adaptive NETwork (AIDANET) system run in a new 
smaller network version, used in full closed loop (FCL) by [CONTACT_166038] T1D.  
Study Design  Randomized crossover, device safety/feasibility supervised house/hotel with transition to home use, interventional trial of AIDANET  
Number of Sites  1 
Endpoint  The primary metric for analysis will be change in mean CGM between the week of the 
control usual -care period and the one -week Remote Monitored At -Home Full Closed Loop 
period using AIDANET.  
Population  Key Inclusion Criteria  
• Age 18- 60 years at time of consent.  
• Clinical diagnosis of T1D, based on investigator assessment, of at least 1 year 
duration.  
Sample Size Complete 6 participants  
Treatment Groups  Randomized Crossover: Participants will be randomized 1:[ADDRESS_192596] the control period before use of the AIDANET system ( Group A) or after use of the AIDANET system 
(Group B). 
Participant Duration  Approximately 3 weeks: approximately 1 week of usual care, 3 day s/2 night s house/hotel  
in FCL, and 1 week At Home Remote Monitored FCL.  
Protocol Overview/Synopsis  We will enroll up to 12 participants with a plan to complete 6 participants. The study will be performed for about 36 hours at a local hotel/rental. Following the house/ hotel session, 
participants will undergo a 7 day/6- night Remote Monitored At -Home use session. We will 
also conduct a one-week control period gathering data on glycemic control and insulin 
administration with the participants usual care therapy. Participants will be randomized 1:1, to either Group A (control period prior to AIDANET use) or Group B (control period after 
AIDANET use).  
CLINICAL PROTOCOL  
 
 
MiniNET _25-Oct-[ADDRESS_192597] Study 
Check -In 
Location  CV/R/ Ph CV/R/ Ph Home x 1 
week  R/Ph  House/  
Hotel  House/  
Hotel  Home x 1 
week  Home  
Visit  1 2 3 4 5 6 7 8 
Timeframe  (days)  [ADDRESS_192598] (if 
applicable)  X        
Blood Testing: 
BMP, Liver 
Functioning, Hematocrit, TSH (if requested by 
[CONTACT_28839]) X        
Physical Exam 
(H&P within 6 
months permitted 
as substitute)  X        
Vital Signs (including height/weight) (self-reported 
values permitted)  X    X    
CLINICAL PROTOCOL  
 
 
MiniNET _25-Oct-2024   Page 8 of 60 
 CV = Clinic Visit; R=Remote Visit; Ph=Phone  which includes text messages and email s Demographic Data 
Survey (if 
eligibility is met)  X        
Randomization    X       
Study Equipment 
Training       X   
CGM Use    X X X X X  
Fully Closed Loop (FCL) Use (e.g. 
AIDANET, DiAs , 
CGM )     X X X  
Questionnaires      X  X  
Concomitant 
Medication Review  X    X    
Review diabetes management and 
AEs   X X X X X X 
CLINICAL PROTOCOL  
 
 
MiniNET _25-Oct-2024   Page 9 of 60 
 Table 2. Metric Capture Timeline  
 Enrollment  1-Week 
Usual Care  Hotel   FCL  1-Week at-
home FCL  
Visit  1 3 5 7 
Demographic Data  x    
HbA1c  x    
CGM Data      
Mean CGM   x x x 
GMI   x x x 
TIR 70 -180 mg/dL   x x x 
CGM StDev   x x x 
CGM CV   x x x 
CGM%<54 mg/dL   x x x 
CGM%<70 mg/dL   x x x 
CGM%>180 mg/dL   x x x 
CGM%>250 mg/dL   x x x 
Time in Automation    x x 
Total Daily Insulin Dose   x x x 
Number of Boluses per Day   x x  
Exercise: CGM %<70 mg/dL    x  
Unannounced Meals: 
% CGM>250 mg/dL    x  
Inspi[INVESTIGATOR_166029]    x x 
Technology Expectations Survey    x x 
  
CLINICAL PROTOCOL  
 
 
MiniNET _25-Oct-2024   Page 10 of 60 
 Table of Contents  1 
Chapter 1:  Background .............................................................................................................. 14 2 
1.1 Introduction ......................................................................................................................... 14 3 
1.2 Study Objective ................................................................................................................... 15 4 
1.3 Specific Aims and Hypotheses ........................................................................................... 15 5 
Chapter 2:  Study Synopsis  ......................................................................................................... 16 6 
2.1 Study Design ....................................................................................................................... 16 7 
2.2 Study Hardware/Software ................................................................................................... 16 8 
2.3 Timing of Device Use ......................................................................................................... 16 9 
2.4 Meal and Exercise Testing  .................................................................................................. 17 10 
2.5 Study Devices Download  .................................................................................................... 18 11 
2.6 Study System Issues ............................................................................................................ 18 12 
Chapter 3:  Study Screening  ....................................................................................................... 19 13 
3.1 Clinical Site  ......................................................................................................................... 19 14 
3.2 Participant Recruitment and Enrollment  ............................................................................. 19 15 
3.3 Informed Consent and Authorization Procedures ............................................................... 19 16 
3.4 Participant Inclusion Criteria  .............................................................................................. 19 17 
3.5 Participant Exclusion Criteria  ............................................................................................. 20 18 
3.6 Screening Procedures .......................................................................................................... 21 19 
3.7 Screen Failures  .................................................................................................................... 22 20 
3.8 Personal Equipment Downloads ......................................................................................... 23 21 
3.9 Questionnaire ...................................................................................................................... 23 22 
3.10 Other Considerations ........................................................................................................ 23 23 
Chapter 4:  Study Devices & Training  ....................................................................................... [ADDRESS_192599]-2024   Page 11 of 60 
 Chapter 5:  Randomization ......................................................................................................... 27 30 
Chapter 6:  Usual Care Control Period  ..................................................................................... 28 31 
6.1 Usual Care Control Period .................................................................................................. 28 32 
6.2 Pre -Hotel Check -In Visit  .................................................................................................... 28 33 
Chapter 7:  Supervised Hotel Fully Closed Loop Period  ......................................................... 29 34 
7.1 Hotel Session  ...................................................................................................................... 29 35 
7.2 Qualifications and Role of the Staff.................................................................................... 29 36 
7.3 Hotel Session Check -In....................................................................................................... 29 37 
7.4 Study Meals ........................................................................................................................ 30 38 
7.5 Hotel Session Activities  ...................................................................................................... 30 39 
7.6 Glycemic Treatment Guidelines  ......................................................................................... 30 40 
7.7 FCL Equipment Training .................................................................................................... 31 41 
7.8 Hotel Session Discharge ..................................................................................................... 31 42 
7.9 Other Issues  ......................................................................................................................... 32 43 
Chapter 8:  Remote Monitored At -Home Fully Closed Loop Period ..................................... [ADDRESS_192600]-Study Check- In ........................................................................................................... 34 48 
8.5 Early Termination Visit (If Applicable)  ............................................................................. 34 49 
8.6 Unscheduled Visits ............................................................................................................. 34 50 
Chapter 9:  Medical Monitor Safety Review  ............................................................................. 35 51 
Chapter 10: Testing Procedures  ................................................................................................ 36 52 
10.1 Laboratory and Point of Care Testing ............................................................................... 36 53 
10.2 Que
stionnaires................................................................................................................... 36 54 
Chapter 11: Risks Associated with the Clinical Trial.............................................................. [ADDRESS_192601]-2024   Page 12 of 60 
 Chapter 12: Adverse Events, Device Issues, and Stoppi[INVESTIGATOR_1869] ........................................... 43 58 
12.1 Definitions ......................................................................................................................... 43 59 
12.2 Reportable Events ............................................................................................................. 44 60 
12.3 Relationship of Adverse Event to Study Device............................................................... 45 61 
12.4 Intensity of Adverse Event................................................................................................ 45 62 
12.5 Coding of Adverse Events ................................................................................................ 46 63 
12.6 Outcome of Adverse Events ............................................................................................. 46 64 
12.7 Reportable Device Issues  .................................................................................................. 47 65 
12.8 Timing of Event Reporting ............................................................................................... 47 66 
12.9 Stoppi[INVESTIGATOR_2121] ............................................................................................................... 48 67 
12.10 Independent Safety Oversight ......................................................................................... 48 68 
12.11 Definition of a Data Breach  ............................................................................................ 49 69 
Chapter 13: Miscellaneous Considerations  .............................................................................. [ADDRESS_192602] to Follow Up ............................................................................................................. 50 74 
Chapter 14: Statistical Consideration  ....................................................................................... 51 75 
14.1 Design and Randomization ............................................................................................... 51 76 
14.2 Sample Size ....................................................................................................................... 51 77 
14.3 Outcome Measures ............................................................................................................ 52 78 
14.4 Safety Analyses  ................................................................................................................. 53 79 
14.5 Baseline Descriptive Statistics  .......................................................................................... 53 80 
14.6 Device Issues  .................................................................................................................... 54 81 
Chapter 15: Data Collection and Monitoring .......................................................................... 55 82 
15.1 Case Report Forms and Device Data  ................................................................................ 55  83 
15.2 Study Records Retention................................................................................................... 55 84 
15.3 Protocol Deviations ........................................................................................................... 55 85 
Chapter 16: Ethics/Protection of Human Participants  ........................................................... [ADDRESS_192603]  ................................................................................................................. 56 87 
16.2 Institutional Review Boards .............................................................................................. 56 88 
16.3 Informed Consent Process ................................................................................................ 56 89 
16.4 Participant and Data Confidentiality  ................................................................................. 57 90 
Chapter 17: References  .............................................................................................................. [ADDRESS_192604]-2024   Page 14 of 60 
 Chapter 1:  Background 94 
 
 95 
A major impediment to maintaining blood glucose (BG) control in Type 1 diabetes (T1D) is missed 96 
meal boluses, which has been associated with significantly higher HbA1c levels.1  While the 97 
advent of the artificial pancreas (AP) offers promise of safe reductions in HbA1c, our research 98 
group previously found that current AP systems only partly compensate  for missed prandial 99 
insulin.2 We thus designed a new system called Automated Insulin Delivery Adaptive NET work, 100 
or AIDANET , to be fully automated, utilizing a Bolus Priming System (BPS) that recognizes meal 101 
ingestion and delivers a quick priming dose of insulin prior to extreme blood sugar excursions. 102 
When used as a fully automated closed loop (FCL) system (without any meal announcements to 103 
the controller), this system improves glucose time -in-target range (TIR) 70 -180 mg/dL compared 104 
to a current commercially available system (Control -IQ).  We subsequently incorporated this [ADDRESS_192605] to be via use on an insulin 107 
pump, requiring a refined “smaller” code set to be able to run on internal pump software.   [ADDRESS_192606] is to assess whether this “smaller” version of AIDANET continues to provide 110 
safe and effective glycemia management as seen in prior formulations.  The current study is a 111 
randomized cross -over study comparing participants’ usual care with one week at home on 112 
AIDANET. The week of control at home will follow a two- night hotel stay when participants will 113 
be taught how to operate the new system  during the at -home portion of the study. The comparator 114 
usual care week will be randomly assigned to being before time on AIDANET (i.e., prior to the 115 
hotel stay) or after (i.e. time after the one-week home portion).  116 
For the majority of time on AIDANET, participants will not announce meal ingestion to the 117 
system —using the system as an FCL system.  However, the system is designed to also be able to [ADDRESS_192607] participants to use the system as follows: 120 
• For one of the dinners in the hotel participants will bolus for carbohydrate content of 121 
their meal, using their usual insulin -to-carbohydrate ratio (while the other dinner in the 122 
hotel will be fully FCL).  123 
• For one full day while at home participants will bolus for carbohydrates for all 124 
ingestions (using their usual insulin- to-carbohydrate ratio). 125 
• For another full day at home, participants will merely announce to the system each time 126 
they begin to eat a meal or snack; this will induce the system to deliver a rapid BPS 127 
dose (e.g. 10% of total daily insulin). 128 
We hypothesize that performances of this smaller version of AIDANET will provide safe and 129 
effective care when used as FCL (with the exception of the hybrid use as just described). We expect [ADDRESS_192608] having an AID system that has potential to be 131 
used embedded in insulin pumps. 132 
 
 133 
This study aims to demonstrate the safety and feasibility of the Automated insulin delivery as 134 
Adaptive NETwork (AIDANET) system in a smaller software version, used as FCL. This study 135 
will also assess differences in glycemia outcomes on assigned days when the participant 1) enters 136 
total carbohydrate amount and 2) announces when food is started to be consumed. 137 
 
 138 
Aim 1 : To evaluate the performance (safety, efficacy) of the smaller version of AIDANET used 139 
as FCL.  140 
Hypothesis:  FCL use will provide as good or better mean CGM value and glucose TIR during [ADDRESS_192609] care sensor data. 142 
Aim 2 : To evaluate the safety and efficacy of the smaller version of AIDANET during days where 143 
participants are assigned to 1) use usual insulin- to-carbohydrate ratio and 2) use meal 144 
announcement alone (triggering BPS). 145 
Hypothesis:  The AIDANET system will yield improved mean CGM glucose and TIR on days [ADDRESS_192610]-2024   Page 16 of 60 
 Chapter 2:  Study Synopsis  149 
 
 150 
This study assesses adults with T1D on the AIDANET system during a 2-night house/ hotel stay 151 
and during 1 week at home (Figure 1). Participants will use the system as FCL with the exception 152 
of using their insulin- to-carbohydrate ratio as usual during 1 dinner in the house/hotel and [ADDRESS_192611] an approximately 1- week control period gathering data on 155 
glycemic control and insulin administration with the participants’ usual care therapy. Participants 156 
will be randomized 1:1 to either Group A (control period prior to AIDANET use) or Group B 157 
(control period after AIDANET use).  158 
 159 
• Figure 1: Device Use Timeline 160 
 
 161 
The study will involve testing a new AID system designed to enable full closed loop control and 162 
consisting of the following elements: the diabetes assistant (DiAs) prototypi[INVESTIGATOR_25586], connected 163 
to a Tandem t:AP research insulin pump and a Dexcom G6 CGM, and implementing a new 164 
“smaller” coding version of the University of Virginia (UVA) AIDANET  algorithm. Upon arrival 165 
at the hotel, participants will be taught how to use the Tandem t:AP pump as well as the DiAs 166 
system, including stoppi[INVESTIGATOR_27981]. 167 
 
 168 
One-Week Control Period : All participants will collect approximately one week of usual care data 169 
to serve as control data for cross -over testing as outlined in Section  6.1. During the control period, 170 
participants may use an insulin pump either in manual or automated mode that is capable of being 171 
downloaded. Participants will be randomized 1:[ADDRESS_192612] the control period before use 172 
of the AIDANET  system ( Group A) or after use of the AIDANET  system ( Group B).  173 Day 2 Day 1
End of
study
Group A :1-week Usual
Care data collec�onScreening ,
enrollmentHotel
Randomiza�onStudy team in contact [CONTACT_166039] -and hyperglycemia alertsHomeDay 3
All meals w /o carb
announcement except
insulin :carb use at
dinner Day 2Group A & B:Remote Monitored At -Home Period
x7 days /6nights
All meals w /o carb or meal announcement , except :
One full day only meal announcement , another full
day with insulin :carb useGroup B :1-week Usual
Care data collec�onSwitch to
usual careHome Home Day 9
Educa�on for
system use at home
2-night hotel stay
using AIDANET
CLINICAL PROTOCOL  
 
 
MiniNET _25-Oct-2024   Page 17 of 60 
 Hotel Period : Participants will arrive at the hotel prior to dinner on the afternoon of Day 1. They 174 
will be connected to the Tandem t:AP pump, which will be connected to the DiAs platform. A 175 
Dexcom G6 CGM may be placed on Day 1 or by [CONTACT_166040] 1 and will also be 176 
connected to the DiAs platform. The system will be started in the afternoon/evening with 177 
AIDANET enabled prior to dinner on Day 1. Participants will be taught how to use the DiAs in 178 
this configuration. The t:AP pump will be programmed with back up parameters determined by 179 
the study investigator(s). Once started, the participants will have their glucose values managed 180 
through use of this system during the hotel and Remote Monitored At-Home periods. 181 
Remote Monitored At -Home Period : Participants will continue to use the Tandem t:AP pump, 182 
DiAs platform running the AIDANET smaller network system, and Dexcom G6 CGM for glucose 183 
control for 7 days/6 nights during this period. At the end of the Remote Monitored At -Home 184 
period, participants will return to their usual diabetes therapy. 185 
 
 186 
 Meal Testing   187 
During the supervised house/ hotel period, participants will be instructed to eat approximately 3 188 
unannounced meals per full day, with the exception of using their usual insulin- to-carbohydrate 189 
ratio with dinner one of the 2 nights. The time of completion for these meals will be recorded by 190 
study staff. The % CGM>250 mg/dL for the 4 hours after each meal will be recorded and 191 
specifically analyzed along with the CGM area under the curve (AUC) for the post -meal [ADDRESS_192613] the timing of the meals. The exception 194 
is they will be instructed for 1 full day (from waking through bedtime) to announce usual insulin- 195 
to-carbohydrate for all ingestions and for another full day to announce when they begin to eat.  196 
Participants will be educated to consume their usual diet during both the at -home control period 197 
and the Remote Monitored At- Home FCL period. 198 
 Exercise Testing   199 
During the supervised hotel period, participants will engage in mild activity (a walk of 200 
approximately 30 minutes) on Day 2. Study staff will set a Temporary Control Rate (TCR) of 201 
approximately 50- 100% starting up to approximately one hour prior to exercise for approximately [ADDRESS_192614] the 203 
duration, approximate intensity (low, moderate, or high intensity), the TBR <70 mg/dL, TBR <54 204 
mg/dL, and any epi[INVESTIGATOR_166030] (SH) during the walk and in the 2 hours after 205 
the exercise challenges. Participants will be provided with an exercise monitor (e.g., Fit bit) for use [ADDRESS_192615] insulin delivery. If the CGM is not connected, the system will 216 
revert to the usual open loop function of the pump and deliver insulin with the pre -programmed 217 
dosing parameters. Resumption of closed- loop control will occur automatically once the CGM 218 
signal is again available.  219 
If the DiAs system is unable to maintain connectivity with the Tandem t:AP pump, the pump will [ADDRESS_192616]-2024   Page 19 of 60 
 Chapter 3:  Study Screening   [ADDRESS_192617] one 229 
year. This enrollment number account s for dropout s or screen failures that may occur. The goal is 230 
to complete a total of approximately 6 participants. 231 
 
 232 
Before consent has been obtained, participants will be asked inclusion/exclusion criteria questions [ADDRESS_192618] been signed by [CONTACT_941] 237 
participant and the study team. 238 
Consenting procedures and documentation are defined in section 16.3. 239 
After informed consent has been signed, a potential participant will be evaluated for study 240 
eligibility through review of medical history, performance of physical exam by a licensed health 241 
care professional, and other testing as needed per the I/E criteria.  [ADDRESS_192619] meet all of the following inclusion criteria in order to be eligible to 244 
participate in the study. 245 
1. Age ≥18.0 and ≤[ADDRESS_192620] three  months ; Any pump, either open loop or [ADDRESS_192621] six months. 251 
5. Willingness to switch to use a commercially approved personal insulin (e.g., lispro or 252 
aspart, or biosimilar approved products) within the study pump as directed by [CONTACT_1758] [ADDRESS_192622] agree to use a form of contraception to 261 
prevent pregnancy while a participant in the study (e.g. hormonal contraception, 262 
abstinence from heterosexual intercourse). A negative serum or urine pregnancy test will 263 
be required for all females of childbearing potential. Participants who become pregnant 264 
will be discontinued from the study. Also, participants who during the study develop and 265 
express the intention to become pregnant within the timespan of the study will be 266 
discontinued. 267 
10. Willingness to use the study FCL system (CGM, pump, and phone) during the relevant 268 
study period. 269 
11. Willingness not to start any new non-insulin glucose-lowering agent during the course of 270 
the trial.  271 
12. Willingness to participate in all study procedures including the house/hotel session, 272 
exercise challenges (e.g., one hour per day during hotel), and to consume approximately [ADDRESS_192623] any exclusion criteria in order to be eligible to participate in the 280 
study.  281 
1. Plans to start a new non-insulin glucose-lowering agent (e.g., GLP-1 receptor agonists, 282 
Symlin, DPP-4 inhibitors, sulfonylureas). Participants may be on a stable dose of such an [ADDRESS_192624] month. 284 
2. Current use of an SGLT-2 or SGLT-1/[ADDRESS_192625] 12 months. 289 
6. History of chronic renal disease (Stage 4 or unstable Stage 3b per investigator judgment) [ADDRESS_192626] approximately 1 -2 hours. The visit may occur in- person or remotely by [CONTACT_166041] 307 
video communication (e.g., Zoom , Webex ) The following procedures may be performed/data 308 
collected/eligibility criteria checked and documented:  309 
1. Inclusion and Exclusion criteria assessed  310 
2. Demographics, including: 311 
a. Date of birth  312 
b. Gender  313 
c. Race  314 
d. Ethnicity  315 
3. Medical History, including diabetes history  316 
a. Duration of disease (number of years) [ADDRESS_192627]-2024   Page 22 of 60 
 9. Surgical history 330 
10. Allergies  331 
11. Concomitant medications  332 
12. Physical Examination – A historical history and physical report within 6 months of 333 
screening appointments may be used but is not required for eligibility. If vitals are not 334 
available, may include self -reported values of all available vitals.  335 
a. Weight  336 
b. Height 337 
c. Blood pressure  338 
d. Temperature  339 
e. Heart Rate  340 
13. Screening Labs  341 
a. HbA1c point of care or laboratory; may use an HbA1c if obtained in the past month.  [ADDRESS_192628] for all women of childbearing potential (this test can 343 
be done remotely with results sent to the study team)  344 
A physical exam documented in the prior 12 months can suffice for the physical exam but will not 345 
serve as an exclusion criterion if not available. Participants may self -report height, weight, blood 346 
pressure, temperature, and heart rate; or these may be obtained by [CONTACT_166042] 347 
visit. An HbA1c value obtained in the previous one month may serve for the enrollment HbA1c 348 
value.  349 
If needed based on medical history, investigators may include baseline chemistry panel, liver 350 
function tests, hematocrit, and thyroid stimulating hormone (lab results within one year of 351 
screening appointment may be used). Any labs required may be obtained at a local laboratory (e.g., [ADDRESS_192629]) convenient to the participant. The study physician or physician designee will [ADDRESS_192630]-2024   Page 23 of 60 
 
 
 363 
Up to 6 months of historical data from the participant’s personal insulin pump, glucometer, or 364 
continuous glucose monitor may be downloaded or recorded. Data will be obtained from the 365 
participant’s personal insulin pump, glucometer  and CGM. This data may be obtained through the 366 
commercial applications (e.g., t:connect, Tidepool, and Dexcom).  367 
 
 368 
Participants will be asked to complete the Demographic Data Survey, as described in section 9.2, 369 
once eligibility has been met. 370 
 
 371 
This study is not meant to find out if the participant has any other disease or problem. The study 372 
leaders will alert the participant if any of the research results are important to the participant’s [ADDRESS_192631]-2024   Page 24 of 60 
 Chapter 4:  Study Devices  & Training  377 
The study system is designed to enable full closed loop control and consisting of the following 378 
elements: the diabetes assistant (DiAs) prototypi[INVESTIGATOR_25586] (smart phone), connected to a Tandem 379 
t:AP research insulin pump and a Dexcom G6 CGM, and implementing a new “smaller” coding 380 
version of the University of Virginia (UVA) AIDANET algorithm. 381 
 
 382 
 Equipment Description.  383 
A study insulin pump will be provided to all participants at the training session. The participants 384 
will be trained in the basic functionality (e.g., bolus menu and infusion set change menu) for the [ADDRESS_192632] is available on- line with relevant sections 386 
applicable to the study pump will be covered. 387 
The  t:AP research CSII pump will be programmed with the participants' usual pump parameters 388 
(basal insulin rate, insulin to carbohydrate ratio, and insulin correction factor) as determined by 389 
the study physician at the onset of the hotel phase. These parameters serve as backup- only settings 390 
for the system in open loop mode, and do not determine behavior of the AIDANET algorithm. The 391 
bolus priming system (BPS) profile determines the maximum fraction of total daily insulin (TDI) 392 
that can be injected by [CONTACT_166043] (e.g., 8% between 06:00 and 10:00). [ADDRESS_192633]. The purpose of this training is to introduce the study syste m to the participant. Insulin 399 
parameters will be determined by [CONTACT_093](s) and programmed into their study insulin pump 400 
and confirmed by [CONTACT_166044]. Participants will then switch to the study insulin pump. The 401 
participant’s personal pump will be removed. The investigator may elect to use an existing [ADDRESS_192634] less frequent CGM users watch the Dexcom online 421 
training videos ( https://www.dexcom.com/training -videos ) to assist in the training session. Study 422 
staff training may include review of the study CGM in real -time to make management decisions 423 
and how to review the data after an upload for retrospective review. Study staff will specifically 424 
identify how alarms are set using the app and the frequency that these alarms will repeat. 425 
For participants not using the Dexcom G6, the participants will be observed placing the sensor and 426 
will learn/review how to access the CGM trace via the Dexcom G6 commercial app (prior to the 427 
hotel session) and via the DiAs phone (during the hotel session). The participants will be asked to 428 
perform fingerstick blood glucose measurements (if needed) in accordance with the labelling of 429 
the study CGM device. An electronic copy of the CGM user’s guide will be provided for the se [ADDRESS_192635] the training session 431 
knowing how to properly use the CGM. The study team will be available for any questions. 432 
The study team will ask participants to share their data to the study Dexcom clinical account. This 433 
requires a one- time confirmation of data sharing between either the participant’s personal Dexcom [ADDRESS_192636] the data from the devices. They may also use 442 
their own Dexcom G6 or G7 CGM.  If the participant elects to use a personal device, the Dexcom 443 
app will be downloaded to their phone in order to monitor the participant’s CGM values and alerts [ADDRESS_192637] strips in accordance with the manufacturer’s labeling.   [ADDRESS_192638] that the app be downloaded 454 
to the participant’s personal phone. The app will permit continued visibility of blood glucose [ADDRESS_192639] strips in accordance 460 
with the manufacturer’s labeling. Urine ketone strips may be provided to the participant for the at - [ADDRESS_192640]-2024   Page 27 of 60 
 Chapter 5:  Randomization  466 
VISIT  2 467 
Once eligibility is met and screening procedures are completed, the participant will proceed to 468 
Randomization. Participants will be randomized 1:1 to assess a 1 -week usual care period before use of 469 
the AIDANET system ( Group A) or after use of the AIDANET system ( Group B).   470 
Participants who screen -fail or dropout will be replaced if  it occurs prior to the Hotel Admission . 471 
Randomization will occur via REDCap  module.  472 
GROUP A: Participants will complete one week at home usual care before the use of the 473 
AIDANET system at the hotel admission.  474 
GROUP B : Participants will complete one week at home usual care after the use of the AIDANET [ADDRESS_192641]-2024   Page 28 of 60 
 Chapter 6:  Usual Care Control Period  [ADDRESS_192642] blood glucose values during 485 
the study. This study team will download this glucometer at the conclusion of the study. 486 
Participants will be instructed to follow their normal routine involving diet, exercise, and insulin 487 
administration.  488 
Any relevant contacts will be recorded on the CRF and summarized as appropriate (e.g. contact 489 
that is not a scheduling or supplies issue will not be recorded).  490 
 
 491 
VISIT 4 492 
All participants  will be contact[CONTACT_166045] 24 -48 hours prior to the hotel 493 
admission. The study team will verify the following information: 494 
a. Inquire about any changes to the participant’s medical history 495 
b. Study equipment (e.g., CGM) has been initiated. A new  CGM sensor will be placed 496 
approximately 24-72 hours prior to the hotel session for proper warm-up. 497 
c. Verify with participant that the goal CGM reading at time of arrival is less than 200 498 
mg/dL; this may require contact [CONTACT_166046] [ADDRESS_192643]-2024   Page 29 of 60 
 Chapter 7:  Supervised Hotel Fully Closed Loop Period  506 
VISIT 5  507 
 
 508 
The study will be performed for about 36 hours at a local hotel/rental. Participants will use the 509 
AIDANET  system in the hotel setting from the afternoon/evening of D ay [ADDRESS_192644] one of whom will 514 
be clinical staff (e.g., nurse, physician, nurse practitioner, physician assistant). There will be a [ADDRESS_192645] one study team member ( maybe trained staff, nurse, physician, NP, or PA) using a web- 518 
based remote monitoring system that has been previously established for DiAs. The web- based 519 
remote monitoring system will display real- time insulin delivery, CGM and other system 520 
information to allow for patient safety monitoring. In addition, study team members will be trained 521 
in all protocol and Glycemic Treatment Guideline procedures. The closed- loop system will be 522 
managed by [CONTACT_166047]- staff supervision, particularly at the time of insulin boluses 523 
(if needed). Glucagon for the emergency treatment of hypoglycemia will be available on- site. [ADDRESS_192646] day of the hotel session. The study team will perform 528 
vital signs and inquire about any changes to the participant’s medical history. Any changes to 529 
medical history will be communicated to the medical physician to ensure continued eligibility and 530 
participation.   531 
The participant ’s CGM reading, and ketone concentration will be recorded. In the event that the 532 
participant’s CGM reading is not between 80-250 mg/dL or ketone concentration is ≥0.6 mmol/L 533 
prior to initiation of the FCL system, the study physician may recommend additional insulin dosing 534 
according to the participants’ usual doses. Study physician may elect to cancel participant’s 535 
participation in the hotel admission if concerned about their medical safety. This participant will 536 
not be replaced.  537 
The participant’s home insulin pump will be discontinued, and the study insulin pump will be 538 
initiated.  The study team will ensure the proper function of the CGM  and insulin pump. The CGM 539 
used in the study is FDA -approved for the non- adjunctive measurement of blood glucose (i.e., the [ADDRESS_192647]-2024   Page 30 of 60 
 CGM reading can be used for insulin dosing decisions). The CGM readings will be the primary 541 
source of blood glucose values. There is no required protocol fingerstick blood glucose 542 
measurements other than at times of CGM calibration (if necessary) and if directed by [CONTACT_1758] [ADDRESS_192648] the time the meal was eaten so that analysis of the 550 
AIDANET algorithm’s performance around the mealtime may be conducted. Participants will use 551 
their usual insulin:carbohydrate ratio at dinner on Day 2. No other meal announcement will occur [ADDRESS_192649] 80 mg/dL in order to begin the walk. The timing 559 
of exercise will be recorded by [CONTACT_166048]’s [ADDRESS_192650] 563 
pain, dizziness, palpi[INVESTIGATOR_814], or any such concerning symptoms reported by [CONTACT_4317]. 564 
Participants will stop their participation in the exercise portion of the study if reporting any 565 
concerning symptoms. Study physicians (or physician’s assistants) will assess the participants for 566 
their need for additional care outside the study. If symptoms resolve entirely and there is no 567 
additional requirement for care outside the study, participants may then continue with the 568 
remainder of the study per investigator discretion.  569 
Participants will also be free to engage in additional low -intensity activity (i.e., walking) during [ADDRESS_192651] the house/hotel.  [ADDRESS_192652]-2024   Page 31 of 60 
 
 Hypoglycemia 577 
a. If CGM falls below 70 mg/dL at any time, confirm  <70mg/dL CGM readings and 578 
potential hypoglycemia symptoms with a fingerstick blood glucose . If blood glucose 579 
confirms <70mg/ dL CGM reading, hypoglycemia will be treated with oral glucose 580 
of approximately 5 -15 g. Participants will be encouraged to wait 15 min prior to 581 
giving a second glucose treatment.  These fingerstick checks will be performed 582 
during the hotel stay and during the home portion if the participant chooses to do so.  583 
During the hotel stay we will also recheck a fingerstick blood glucose before 584 
retreatment.   585 
b. If a participant experiences any symptoms of hypoglycemia (e.g., shakiness, 586 
dizziness, sweating, pallor, clumsiness, difficulty paying attention, or tingling 587 
around the mouth), then the participant should treat with oral glucose of 5- 15 g. 588 
Participants will be encouraged to wait 15 min prior to giving a second glucose 589 
treatment.   During the hotel portion of the study, a fingerstick blood glucose will be 590 
assessed before such treatment for symptoms and before any re- treatment.  591 
c. If a participant displays  any signs of neuroglycopenia (e.g., lethargy, disorientation, 592 
confusion, or inappropriate behavior) or severe hypoglycemia (e.g., hypoglycemic 593 
seizure, loss of consciousness, inability to properly consume treatment) 594 
hypoglycemia will be treated with either oral glucose or glucagon. The patient will 595 
be discharged from the study. The participant should consult with a study physician 596 
to discuss next steps for broader evaluation of symptoms unrelated to hypoglycemia. 597 
 Hyperglycemia  598 
If CGM value is >300 mg/dL for 2 hours or >400 mg/dL at any time, check fingerstick BG and 599 
ketone level every 60±15 minutes. If unexplained hyperglycemia, evaluate the integrity of the 600 
insulin site, consider changing the site and providing a correction bolus as recommended by [CONTACT_941] 601 
bolus calculator. If insulin is given subcutaneous injection rather than through the DiAs, closed- 602 
loop control should be suspended for up to four hours unless directed by a study clinician. 603 
 
 604 
VISIT 6  605 
Participants will receive training on at- home use of the study system, safety protocols, and at -home 606 
study contacts on the day of discharge. Study equipment training is described in section Chapter 607 
4:.  [ADDRESS_192653] the staff on -call in the event of subcutaneous insulin need. If insulin is delivered by [CONTACT_31617] 617 
means other than the study pump, the participant will be instructed to turn off closed -loop mode 618 
for approximately four hours . This timeframe  can be adjusted  by [CONTACT_5989]. 619 
The participant will also be asked to alert the study clinical staff for technical issues with the 620 
Tandem research pump and/or the DiAs system, including use of the study pump and study CGM 621 
(open loop mode) during periods of component disconnections or technical difficulties.  [ADDRESS_192654]-2024   Page 33 of 60 
 Chapter 8:   Remote Monitored At -Home Fully Closed Loop Period 625 
VISIT 7 626 
 
 627 
Upon discharge on day 3 of the hotel period, participants will begin a 7 day/6-night Remote 628 
Monitored At -Home  stage of the study. Participants will continue to wear the FCL research system 629 
as initiated during the hotel period. Participants will be instructed to eat approximately 3 freely 630 
chosen meals per day without announcing them to the system. The exception is that on 2 separate 631 
days participants will 1) announce all food intake (triggering an immediate BPS dose) and 2) use 632 
their usual insulin -to-carbohydrate ratio for all food ingestion. Participants will be instructed to 633 
participate in their usual level of physical activity. Participants will complete the study after lunch 634 
on overall study day 9 ( Day 7 of the home portion), at which point they will return to use of their 635 
usual diabetes care.  636 
Participants in Group A will complete the study after this 1 -week FCL data collection period. 637 
Participants in Group B will then begin the Usual Care  control period for data comparison (see  638 
section 6.1). 639 
 
 640 
All participants will continue to be remote monitored during the At-Home period of the study 641 
using the connection between DiAs and Diabetes Web Monitoring (DWM) platform at UVA. 642 
Study staff may review the AID system data on the DWM platform as needed; in addition, at each 643 
site, a licensed medical provider (MD, PA, NP, RN, CDCES) will receive the following automated 644 
alerts from the DWM (automated notification system, ANS): 645 
1. CGM > 300 mg/dL for 1 hour. 646 
2. CGM < 70 mg/dL for 20 minutes. 647 
3. CGM < 55 mg/dL at any point. 648 
4. No sensor data for > [ADDRESS_192655] study participants (e.g., call, text, or video chat) and/or their [ADDRESS_192656] (e.g., phone, text, email, etc.) with the study team will occur as needed. Any relevant 654 
contacts will be recorded on the CRF  and summarized as appropriate (e.g. contact [CONTACT_166049] a 655 
scheduling or supplies issue will not be recorded ).  656 
 
 657 
All participants will complete the INSPI[INVESTIGATOR_166031] : [ADDRESS_192657]-2024   Page 34 of 60 
 • Prior to initiating the study equipment at the hotel admission  659 
• At the conclusion of the one week  of At -Home FCL  data collection .  [ADDRESS_192658] the participant via 663 
phone/email/text/video to:  664 
• Ask about any changes to the participant’s  medical history and medication.  665 
• Review any hypoglycemic events that are less than 60 mg/dL. 666 
• Review any hyperglycemic events that are more than 300 mg/dL . 667 
• Verify that questions have been answered. The study physician or designee will be 668 
available for any  questions related to insulin adjustments/parameters.  [ADDRESS_192659]-Study Check -In Visit (visit 8) in the event of a [ADDRESS_192660]-2024   Page 35 of 60 
 Chapter 9:   Medical Monitor Safety Review  678 
The Medical Monitor  will review compi[INVESTIGATOR_91100]. In addition, 679 
the Medical Monitor  will review all DKA and severe hypoglycemia irrespective of relatedness to 680 
study device use, and all serious events (including UADEs) related to study device use at the time [ADDRESS_192661] s (ADE ) [ADDRESS_192662]-2024   Page 36 of 60 
 Chapter 10:   Testing Procedures 686 
 
 687 
 HbA1c  688 
A blood sample (either capi[INVESTIGATOR_166032]) will be obtained at screening to obtain a baseline [ADDRESS_192663] obtained within 4 weeks prior to enrollment may be used. 690 
HbA1c level may be measured by [CONTACT_166050]2000, a comparable point of care 691 
device, at time of screening. Labs may be obtained at a local laboratory (e.g., LabCorp, Quest ) [ADDRESS_192664] be negative to participate in the study. 696 
 
 697 
 Demographic Data Survey 698 
Research in diabetes technology has revealed significant disparities in minoritized population’s 699 
representation in clinical trials and access to devices that improve diabetes outcomes. Collection 700 
of detailed demographic data regarding participants in technology trials has become essential. This 701 
includes data on race/ethnicity, income levels and insurance status, as well as education and other 702 
variables that describe the study population.  703 
The Demographic Data Survey will be electronically administered once eligibility has been met. 704 
The below information will be gathered for all participants. 705 
a. Age 706 
b. Gender  707 
c. Race  708 
d. Ethnicity  709 
e. Martial status  710 
f. Level of education  711 
g. Employment status  712 
h. Household income 713 
i. Health insurance status  714 
j. Monthly insulin costs and co-payments 715 
  INSPI[INVESTIGATOR_166033]  716 
The self -administered INSPI[INVESTIGATOR_21392] (INsulin Dosing Systems: Perceptions, Ideas, Reflections and 717 
Expectations) questionnaires have been developed to determine the psychosocial impact of AID [ADDRESS_192665]-2024   Page 37 of 60 
 systems in a range of relevant factors specific to youth with T1D (8- 17 years of age) and adults 719 
with T1D, as well as parents/caregivers of youth with T1D, and partners of adults with T1D.  720 
The questionnaire will be administered at the onset of hotel admission and at the conclusion of the 721 
study.  722 
 Technology Expectations Survey  723 
Participants will complete a Technology Expectation/ Acceptance Survey which includes questions [ADDRESS_192666]-2024   Page 38 of 60 
 Chapter 11:  Risks Associated with the Clinical Trial 729 
 
 730 
Risks and Benefits are detailed below. Loss of confidentiality is a potential risk; however, data are 731 
handled to minimize this risk.  Hypoglycemia, hyperglycemia and ketone formation are always a 732 
risk in participants with type 1 diabetes and participants will be monitored for these symptoms.  733 
 Venipuncture Risks  734 
A hollow needle/plastic tube will be placed in the arm for taking blood samples. Blood draws can [ADDRESS_192667] for several weeks.  The risk of local 743 
infection is less than 1 in 1000. This should not be a significant contributor to risks in this study 744 
as finger sticks are part of the usual care for people with diabetes. 745 
 Subcutaneous Catheter Risks (CGM)  746 
Participants using the CGM will be at minimal risk  for developi[INVESTIGATOR_007] a local skin infection at the site 747 
of the sensor needle placement.  If a needle is left under the skin for more than 24 hours , it is 748 
possible to get an infection where it goes into the skin, with swelling, redness and pain. There may 749 
be bleeding where the catheter is put in and bleeding under the skin causes a bruise (1 in 10 risk). [ADDRESS_192668] a small portion of the sensor under the skin that may cause redness, swelling, or pain at the 752 
insertion site.  The participant should be further instructed to notify the study coordinator 753 
immediately if this occurs.  754 
 Risks of Hypoglycemia  755 
As with any person having type 1 diabetes and using insulin, there is always a risk of having low 756 
blood sugar (hypoglycemia). The frequency of hypoglycemia should be no more and possibly less [ADDRESS_192669] as at home, there is the possibility of fainting or seizures 759 
(convulsions) and that for a few days the participant may not be as aware of symptoms of [ADDRESS_192670] approved the insulin 769 
pump, CGM, glucometer and ketone meter for individual use  and that by [CONTACT_166051] 770 
multiple patients, bloodborne pathogens (i.e. Hepatitis B) may be spread through the use of 771 
multiple users.  772 
The study CGM system is labelled  for single patient  use only. The sensor (the component of the 773 
system that enters the skin) will be individual use  only. The transmitter and receiver may be reused 774 
during the study after  the study team cleans  the device using a hospi[INVESTIGATOR_307] -approved cleaning 775 
procedure. The transmitter is attached to the sensor but does not enter the skin and the receiver, if 776 
used, is a handheld device.  777 
CGM cleaning instructions are provided in the Dexcom G4 Platinum (Professional) Cleaning and 778 
Disinfection manual (current edition) and a similar approach will be applied for the CGMs  used in 779 
this study. 780 
The study insulin pumps are labelled  for single  patient use. During the study, this device may be 781 
reused after the study team cleans  the device with a  hospi[INVESTIGATOR_307]- approved cleaning procedure. All 782 
infusion set equipment will be single patient use only (infusion set insertion kits, tubing, cartridges 783 
etc.)   [ADDRESS_192671] with the equipment to download the device. 787 
The study team will clean the ketone meter per manufacturer directions.  788 
 Device Cleaning Instructions  789 
Members of the study team will clean the study equipment after use as noted in these instructions. 790 
CGM cleaning instructions are provided in the Dexcom G4 PLATINUM (Professional) Cleaning 791 
and Disinfection manual (current edition). The transmitter should be cleaned with Clorox 792 
Healthcare® Bleach Germicidal Cleaner or any disinfectant product in a spray bottle containing a [ADDRESS_192672] with EPA registration number [ZIP_CODE]-7 using similar procedures as the cleaning process.   800 
Per the pump manufacturer, the insulin pump will be cleaned with a damp lint -free cloth. Use of 801 
household or industrial cleaners, solvents, bleach, scouring pads, chemicals, or sharp instruments 802 
are prohibited. The pump should never be submerged in water. If needed, use only a very mild 803 
detergent, such as a bit of liquid soap with warm water. A soft towel will be used to dry the pump.  804 
The glucometer is cleaned and disinfected with two separate Super Sani -Cloths (EPA number 805 
9480-4). The entire surface will be cleaned, making sure the surface stays wet for 2 minutes. This 806 
step is repeated with a clean cloth for disinfecting the device.  807 
The Precision Xtra User’s Guide suggests that healthcare professionals use 10% bleach, 70% 808 
alcohol or 10% ammonia to clean the device.  [ADDRESS_192673] skin will be cleaned with ethyl or isopropyl alcohol (70- 90%), 810 
quaternary ammonium germicidal detergent (i.e. Cavicide, EPA number [ZIP_CODE]) or household [ADDRESS_192674] time on the surface depends on the method used to clean the equipment. 812 
Cavicide requires three minutes on the surface of the equipment. Clorox Germicidal Bleach Wipes 813 
require two minutes on the equipment. The surface should remain wet (i.e. slightly damp) with the [ADDRESS_192675] current recommendations.  817 
There is the risk of blood sampling collection and contamination from sampling techniques. Hand 818 
washing with either soap & water or waterless hand sanitizer will be used prior to caring for the [ADDRESS_192676]’s protection (i.e. hand washing, 821 
changing gloves frequently, disposing needles properly). Gloves will be removed, and hands [ADDRESS_192677]’s room. Soiled linen will be 823 
changed to minimize the transfer of pathogenic organisms. 824 
 Hb1Ac Risk  825 
An NGSP Point of Care analyzer (i.e. DCA Vantage Analyzer) will be utilized at the research site [ADDRESS_192678]’s HbA1c level. 827 
 Other Risks  828 
Some participants may develop skin irritation or allergic reactions to the adhesives used to secure 829 
the CGM, or to secure the insulin infusion sets for the continuous subcutaneous insulin infusion.  830 
If these reactions occur, different adhesives or “under -tapi[INVESTIGATOR_007]” (such as with IV 3000, Tegaderm, [ADDRESS_192679]-2024   Page 41 of 60 
 etc.) will be tried, sites will be rotated frequently, and a mild topi[INVESTIGATOR_91101] 832 
medication may be required. 833 
Whenever the skin is broken there is the possibility of an infection. The CGM and pump infusion 834 
sites are inserted under the skin. It is possible that any part that is inserted under the skin may cause 835 
an infection. These occur very infrequently, but, if an infection was to occur, oral and/or topi[INVESTIGATOR_2855] 836 
antibiotics can be used. The risk of skin problems could be greater if you use a sensor for longer 837 
than it is supposed to be used. Therefore, participants will be carefully instructed about proper use 838 
of the sensor. 839 
Data downloaded from the CGM, insulin pump, glucometer,  and ketone meter will be collected 840 
for the study as measures of diabetes self -management behaviors.  Some people 841 
may be uncomfortable with the researchers' having such detailed information about their daily 842 
diabetes habits.  843 
 Known Potential Benefits  844 
It is anticipated  that this protocol will yield increased knowledge about using an automated 845 
closed -loop system with anticipatory action to control glucose levels. The individual participant 846 
may not benefit from study participation. 847 
 Risk Assessment  848 
Based on the facts that (1) adults and adolescents with diabetes experience mild hypoglycemia and 849 
hyperglycemia frequently as a consequence of the disease and its management, (2) the study 850 
intervention involves periodic automated insulin dosing that may increase the likelihood of 851 
hypoglycemia, and periodic automated attenuation of insulin delivery that may increase the 852 
likelihood of hyperglycemia, (3) mitigations are in place, and have been tested in prior studies 853 
using the investigational device system in the home setting, that limit the likelihood of excessive 854 
insulin dosing or prolonged withdrawal of insulin, and (4) rapid reversal of hypoglycemia and [ADDRESS_192680] their origin in the Declaration of Helsinki, with the 862 
protocol described herein, and with the standards of Good Clinical Practice (GCP). [ADDRESS_192681] that the closed loop 866 
system is experimental. Therefore, an investigational device exemption (IDE) from the U.S. Food 867 
and Drug Administration (FDA) is required to conduct the study.  [ADDRESS_192682]-2024   Page 43 of 60 
 Chapter 12:  Adverse Events, Device Issues, and Stoppi[INVESTIGATOR_1869]  869 
 
 870 
 Adverse Events (AE)  [ADDRESS_192683] medical occurrence in a study participant, irrespective of the relationship between 872 
the adverse event and the device(s) under investigation (section 12.2) for reportable adverse events 873 
for this protocol). [ADDRESS_192684] will not be considered an adverse event.  875 
 Serious  Adverse Event (SAE)  [ADDRESS_192685] medical occurrence that: 877 
• Results in death. 878 
• Is life -threatening; (a non -life-threatening event which, had it been more severe, might [ADDRESS_192686] become life-threatening, is not necessarily considered a serious adverse event). 880 
• Requires inpatient hospi[INVESTIGATOR_1081]. 881 
• Results in persistent or significant disability/incapacity or substantial disruption of the [ADDRESS_192687] normal life functions ( life threatening). 883 
• Is a congenital anomaly or birth defect. 884 
• Is considered a significant medical event by [CONTACT_13656] 885 
(e.g., may jeopardize the participant or may require medical/surgical intervention to 886 
prevent one of the outcomes listed above). [ADDRESS_192688] (UADE)  [ADDRESS_192689], problem, or death was not previously identified in nature, 890 
severity, or degree of incidence in the investigational plan or application (including a 891 
supplementary plan or application), or any other unanticipated serious problem associated with a 892 
device that relates to the rights, safety, or welfare of participants (21 CFR 812.3(s)). [ADDRESS_192690] (ADE)  [ADDRESS_192691]-2024   Page 44 of 60 
 to meet its performance specifications or otherwise perform as intended. Performance 902 
specifications include all claims made in the labeling for the device. The intended performance of 903 
a device refers to the intended use for which the device is labeled or marketed. (21 CFR 803.3).   [ADDRESS_192692] medical occurrence that meets 906 
one of the following criteria: 907 
• A serious adverse event as defined in section 12.1.2. 908 
• An Adverse Device Effect as defined in section 12.1.4, unless excluded from reporting 909 
in section 12.7. 910 
• An Adverse Event as defined in section 12.1.1 occurring in association with a study 911 
procedure. 912 
• An AE as defined in section 12.1.1 which leads to discontinuation of a study device for 913 
4 or more hours during the hotel phase and 12 or more hours during the at home phase.  914 
• Hypoglycemia meeting the definition of severe hypoglycemia as defined in section 915 
12.2.1 916 
• Diabetic ketoacidosis (DKA) as defined in section 12.2.[ADDRESS_192693] . Skin reactions from sensor placement are 920 
only reportable if severe and/or required treatment. [ADDRESS_192694] is only reportable as an adverse event 923 
when the following definition for severe hypoglycemia is met:   924 
• The event required assistance of another person due to altered consciousness, and 925 
required another person to actively administer carbohydrate, glucagon, or other 926 
resuscitative actions.  927 
• Impaired cognitively to the point that he/she was unable to treat himself/herself, was 928 
unable to verbalize his/ her needs, was incoherent, disoriented, and/or combative, or 929 
experienced seizure or coma. These epi[INVESTIGATOR_91103] 930 
neuroglycopenia to induce seizure or coma. 931 
• If plasma glucose measurements are not available during such an event, neurological 932 
recovery attributable to the restoration of plasma glucose to normal is considered 933 
sufficient evidence that the event was induced by a low plasma glucose concentration.  934 
 Hyperglycemia Events/Diabetes Ketoacidosis  [ADDRESS_192695] is only reportable as an adverse 936 
event when one of the following four criteria is met:  [ADDRESS_192696]-2024   Page 45 of 60 
 • The event involved DKA, as defined by [CONTACT_3467] 938 
(DCCT) and described below. 939 
• Evaluation or treatment was obtained at a health care provider facility for an acute event 940 
involving hyperglycemia or ketosis. 941 
• Blood ketone level ≥1.5 mmol/L and communication occurred with a health care 942 
provider at the time of the event. 943 
• Blood ketone level ≥3.0 mmol/L, even if there was no communication with a health 944 
care provider.  945 
Hyperglycemic events are classified as DKA if the following are present:  946 
• Symptoms such as polyuria, polydipsia, nausea, or vomiting. 947 
• Serum ketones ≥1.5 mmol/L or large/moderate urine ketones. 948 
• Either arterial blood pH <7.30 or venous pH <7.24 or serum bicarbonate <15. 949 
• Treatment provided in a health care facility.  950 
All reportable Adverse Events —whether volunteered by [CONTACT_2299], discovered by [CONTACT_3449] [ADDRESS_192697], or other 952 
means —will be reported on an adverse event form online.  Each adverse event form is reviewed [ADDRESS_192698] been caused by [CONTACT_19911]. 958 
To ensure consistency of adverse event causality assessments, investigators should apply the 959 
following general guideline when determining whether an adverse event is related: 960 
• RELATED: There is a plausible temporal relationship between the onset of the adverse 961 
event and the study intervention, and the adverse event cannot be readily explained by 962 
the participant’s clinical state, intercurrent illness, or concomitant therapi[INVESTIGATOR_014]; and/or the 963 
adverse event follows a known pattern of response to the study intervention; and/or the 964 
adverse event abates or resolves upon discontinuation of the study intervention or dose 965 
reduction and, if applicable, reappears upon re- challenge.  966 
• UNRELATED: Evidence exists that the adverse event has an etiology other than the 967 
study intervention (e.g., preexisting medical condition, underlying disease, intercurrent 968 
illness, or concomitant medication); and/or the adverse event has no plausible temporal 969 
relationship to study intervention. 970 
 
 971 
The intensity of an adverse event will be rated on a three -point scale: (1) mild, (2) moderate, or (3) 972 
severe.  It is emphasized that the term severe is a measure of intensity: thus, a severe adverse event [ADDRESS_192699]-2024   Page 46 of 60 
 is not necessarily serious. For example, itching for several days may be rated as severe, but may 974 
not be clinically serious. 975 
• MILD: Usually transient, requires no special treatment, and does not interfere with the 976 
participant’s daily activities.  977 
• MODERATE: Usually causes a low level of inconvenience or concern to the 978 
participant and may interfere with daily activities but is usually ameliorated by [CONTACT_3469] 979 
therapeutic measures.  980 
• SEVERE: Interrupts a participant’s usual daily activities and generally requires [ADDRESS_192700] categories (i.e., mild, moderate, severe).  The Medical 984 
Monitor will review the investigator’s assessment of causality and may agree or disagree.  Both 985 
the investigators and Medical Monitor’s assessments will be recorded.  The Medical Monitor will [ADDRESS_192701] the final say in determining the causality. 987 
Adverse events that continue after the participant’s discontinuation or completion of the study will 988 
be followed until their medical outcome is determined or until no further change in the condition 989 
is expected.  990 
 
 991 
The outcome of each reportable adverse event will be classified by [CONTACT_3470]: 992 
• RECOVERED/RESOLVED – The participant recovered from the AE/SAE without [ADDRESS_192702] the AE/SAE stop date. 994 
• RECOVERED/RESOLVED WITH SEQUELAE – The event persisted and stabilized [ADDRESS_192703] the AE/SAE stop date. 996 
• FATAL – A fatal outcome is defined as the SAE that resulted in death. Only the event 997 
that was the cause of death should be reported as fatal. AEs/SAEs that were ongoing at 998 
the time of death; however, were not the cause of death, will be recorded as “resolved” 999 
at the time of death.  1000 
• NOT RECOVERED/NOT RESOLVED (ONGOING) – An ongoing AE/SAE is 1001 
defined as the event was ongoing with an undetermined outcome. 1002 
• An ongoing outcome will require follow -up by [CONTACT_3471] 1003 
outcome of the AE/SAE. 1004 
• The outcome of an ongoing event at the time of death that was not the cause of death, 1005 
will be updated and recorded as “resolved” with the date of death recorded as the stop 1006 
date.  1007 
• UNKNOWN – An unknown outcome is defined as an inability to access the participant 1008 
or the participant’s records to determine the outcome (for example, a participant that [ADDRESS_192704] to follow -up). [ADDRESS_192705]-2024   Page 47 of 60 
 All clinically significant abnormalities of clinical laboratory measurements or adverse events 1011 
occurring during the study and continuing at study termination should be followed by [CONTACT_941] 1012 
participant’s physician and evaluated with additional tests (if necessary) until diagnosis of the [ADDRESS_192706] 1018 
the participant until the adverse event has resolved or stabilized. 1019 
 
 1020 
All UADEs, ADEs, device complaints, and device malfunctions will be reported irrespective of 1021 
whether an adverse event occurred, except in the following circumstances.  1022 
The following device issues are anticipated and will not be reported but will report  as an Adverse 1023 
Event if the criteria for AE reporting described above are met:  1024 
• Component disconnections 1025 
• CGM sensors lasting fewer than the number of days expected per CGM labeling 1026 
• CGM tape adherence issues  1027 
• Pump infusion set occlusion not leading to ketosis 1028 
• Battery lifespan deficiency due to inadequate charging or extensive wireless 1029 
communication  1030 
• Intermittent device component disconnections/communication failures not leading to 1031 
system replacement  1032 
• Device issues clearly addressed in the user guide manual that do not require additional 1033 
troubleshooting 1034 
• Skin reactions from CGM sensor placement or pump infusion set placement that do not 1035 
meet criteria for AE reporting  1036 
 
 1037 
• UADEs must be reported within [ADDRESS_192707].  1039 
• Other reportable adverse events, device malfunctions (with or without an adverse 1040 
event) and device complaints should be reported promptly, but there is no formal 1041 
required reporting period. 1042 
• The IDE Sponsor will investigate the UADE and if indicated, report the results of the 1043 
investigation to the IRBs, FDA, and Medical Monitor  within 10 working days of the 1044 
study team becoming aware of the UADE per 21CFR 812.46(b) (2).  1045 
• The Medical Monitor  will determine if the UADE presents an unreasonable risk to [ADDRESS_192708] receipt notice of the UADE.  1050 
• In the case of a device system component malfunction (e.g. pump, CGM, control 1051 
algorithm), information will be forwarded to the responsible manufacturer by [CONTACT_1758] 1052 
personnel. 1053 
 
 1054 
 Participant Discontinuation  1055 
A participant will be discontinued if any of the following occur: 1056 
• The investigator believes it is unsafe for the participant to continue the intervention.  1057 
This could be due to the development of a new medical condition or worsening of an 1058 
existing condition; or participant behavior contrary to the indications for use of the 1059 
device that imposes on the participant’s safety  1060 
• The participant requests that the treatment be stopped  1061 
• Two distinct epi[INVESTIGATOR_3414] 1062 
• Two distinct severe hypoglycemia events as defined in section 12.2.1. 1063 
• Two events of any kind: severe hypoglycemia or DKA 1064 
 Suspending/Stoppi[INVESTIGATOR_3396]  1065 
In the case of an unanticipated system malfunction resulting in a severe hypoglycemia or severe 1066 
hyperglycemia event (as defined in section 12.2.2), use of the study device system will be [ADDRESS_192709] severe hypoglycemia events as 1069 
defined in section 12.2.1 occur, the overall study would be suspended while the underlying 1070 
conditions are determined.   1071 
In addition, study activities could be similarly suspended if the manufacturer of any constituent 1072 
study device requires stoppage of device use for safety reasons (e.g., product recall). The affected [ADDRESS_192710] 1077 
suspension of study activities or stoppage of the study if deemed necessary based on the totality 1078 
of safety data available.  1079 
 
 1080 
A Medical Monitor  will review all DKA and severe hypoglycemia irrespective of relatedness to 1081 
study device use, and all serious events (including UADEs) related to study device use at the time [ADDRESS_192711] (43 USC [ZIP_CODE]) as an unauthorized acquisition, 1088 
access, or use of protected health information (PHI) that compromises the security or privacy of [ADDRESS_192712]-2024   Page 50 of 60 
 Chapter 13:   Miscellaneous Considerations  [ADDRESS_192713] their personal 1093 
physician to change their prescribed personal insulin to lispro or aspart for the duration of the trial. 1094 
The study devices (study insulin pump, study CGM) must be removed before Magnetic Resonance 1095 
Imaging (MRI), Computed Tomography (CT) or diathermy treatment. Participants may continue [ADDRESS_192714] known outcome/contact [CONTACT_6635]. A participant will be [ADDRESS_192715]-2024   Page 51 of 60 
 Chapter 14:  Statistical Consideration [ADDRESS_192716] can explain part of the benefit of the FCL system during the at -home 1124 
period. 1125 
a. Null Hypothesis: There is no difference in the mean CGM between the week of 1126 
Usual Care observational period and the at-home FCL period. 1127 
b. Alternative Hypothesis: There is a difference in the mean CGM between the week [ADDRESS_192717] and baseline HbA1c and gender as covariates.  1131 
Secondary outcomes: 1132 
All secondary outcomes will be similarly analyzed. If an outcomes distribution is not suited for 1133 
mixed model analysis (e.g., profound skewness, or large atom at boundary) we will perform paired [ADDRESS_192718] (and loose the capacity to use covariate) to test difference in the median 1135 
instead of the mean; this is expected for time below 70mg/dL, number of hypoglycemia, and 1136 
possibly time above 250mg/dL. [ADDRESS_192719] metrics 1155 
recommended by [CONTACT_166052], GMI derived from 1156 
mean CGM, time in range 70 -180 mg/dL, CGM standard deviation (StDev), CGM coefficient of 1157 
variation (CV), CGM %<54 mg/dL, CGM %<70 mg/dL, CGM %>180 mg/dL, and CGM %>250 1158 
mg/dL. For the Usual Care period, CGM data will be obtained from either the participant’s [ADDRESS_192720] their 1166 
pump uploaded at the end of the period to capture their insulin delivery and bolus data. The FCL 1167 
period, insulin use,  and bolus data (if any) will be captured from the experimental device. 1168 
Exercise Challenge Metrics  will include the duration of exercise, approximate intensity of exercise 1169 
(low, moderate, or high intensity), the % CGM<70 mg/dL, % CGM<54 mg/dL, and any epi[INVESTIGATOR_1841] 1170 
of SH (CGM<70mg/dL for more than 15 minutes with interruption, CGM≥70, of less than 15 1171 
minutes or CHO treatment) during and 2 hours after the exercise challenges. 1172 
Unannounced Meal Metrics  during the supervised house/hotel FLC stage participants will be [ADDRESS_192721] 3 meals per day. The time of completion for these meals will be recorded 1174 
by [CONTACT_464]. The % CGM>250 mg/dL for the [ADDRESS_192722] the timing of the meals for unannounced meals.  1177 
Patient Reported Outcomes will include several surveys aiming to capture participant satisfaction 1178 
with the FCL device and any changes in distress or burden of diabetes management. See 1179 
APPENDIX for survey tools. These surveys will include: [ADDRESS_192723]-2024   Page 53 of 60 
 a. The INSPI[INVESTIGATOR_166034]: A validated tool assessing the positive expectancies of AID 1181 
systems for youth, adults, and parents and partners of people with diabetes. This tool 1182 
has been specifically endorsed by [CONTACT_166053][INVESTIGATOR_28525]-dosing 1183 
systems.  1184 
b. Technology Expectations Surveys: A [ADDRESS_192724] of the technology on 1186 
quality of life. Validated to age 13+ years. 1187 
These surveys will be administered at baseline and then at the end of the prior  to or at the start of 1188 
the 1 -week supervised House/Hotel FCL period and at the end of the 1- week remote-monitored 1189 
at-home FCL study 1190 
 CGM Data Treatment  1191 
a. Saturated CGM values “High” and “Low” will be replaced by 401mg/dL and 1192 
39mg/dL respectively.  1193 
b. Any CGM gaps shorter than 1 hour will be interpolated  1194 
c. CGM data during recorded occlusion event will be removed from analysis as 1195 
follows : any measurement less than 2h before or after the time of record will be 1196 
removed. 1197 
d. CGM data following a pump/DiAs communication interruption >1h by [CONTACT_21316] 2h [ADDRESS_192725] 80% of the analysis window CGM measurements (after 1201 
data treatment) are available.  1202 
 
 1203 
We will assess for the system’s functionality, including the ability of the system to run its code 1204 
without error (delivering insulin safely, as planned), as well as its ability to avoid low BG <70 1205 
mg/dL. 1206 
 
 1207 
Baseline demographic and clinical characteristics of the cohort of all randomized participants will 1208 
be summarized in a table using summary statistics appropriate to the distribution of each variable. 1209 
Descriptive statistics will be displayed overall and by [CONTACT_1570].  1210 
Will include: [ADDRESS_192726]-2024   Page 54 of 60 
 d. Race/ethnicity  1215 
e. CGM use before enrollment 1216 
f. AID use before enrollment 1217 
g. Diabetes duration  1218 
h. BMI  1219 
i. Total Daily Insulin  1220 
 
 1221 
The following tabulations and analyses will be performed during time on the UVa AP systems to 1222 
assess device issues:  [ADDRESS_192727] and other reported device issues 1224 
b. % time CGM data available  1225 
c. % time with closed loop control   [ADDRESS_192728]-2024   Page 55 of 60 
 Chapter 15:  Data Collection and Monitoring  1227 
 
 1228 
The study data are collected through a combination of case report forms (electronic and paper) and [ADDRESS_192729].  These documents should be retained for a longer 1240 
period, however, if required by [CONTACT_427].  No records will be destroyed without the written 1241 
consent of the sponsor, if applicable.  It is the responsibility of the sponsor to inform the 1242 
investigator when these documents no longer need to be retained. 1243 
 
 1244 
A protocol deviation is any noncompliance with the clinical trial protocol, Good Clinical Practices 1245 
(GCP), or procedure requirements.  The noncompliance may be either on the part of the participant, [ADDRESS_192730]-2024   Page 56 of 60 
 Chapter 16:  Ethics/Protection of Human Participants  1250 
 
 1251 
The investigator will ensure that this study is conducted in full conformity with Regulations for 1252 
the Protection of Human Participants of Research codified in 45 CFR Part 46, 21 CFR Part 50, 21 1253 
CFR Part 56, and/or the ICH E6. 1254 
 
 1255 
The protocol, informed consent form(s), recruitment materials, and all participant materials will [ADDRESS_192731] be obtained before any participant is enrolled.  Any amendment to the protocol will 1258 
require review and approval by [CONTACT_3484].  All 1259 
changes to the consent form will be IRB approved; a determination will be made regarding whether 1260 
previously consented participants need to be re- consented.  1261 
 
 1262 
 Consent Procedures and Documentation  1263 
Informed consent is a process that is initiated prior to an individual’s agreement to participate in 1264 
the study and continues throughout the individual’s study participation. The potential participant 1265 
will be provided with a short overview of the study including its study goals, study procedures, 1266 
and study timeline. If the potential participant remains interested, they will be asked permission to 1267 
review inclusion/exclusion criteria to assess if they are eligible to participate in the study. If 1268 
permission is granted, the study team will review the Inclusion/Exclusion criteria (section 3.4 and 1269 
3.5). If eligible, the study team member will provide a copy of the informed consent form (e.g., in 1270 
person, email, fax, or mail) to the potential participant for their review. Potential participants may [ADDRESS_192732] to review the informed consent form prior to discussing pre-screening questions.  1272 
The potential participant will be provided with ample time to read and review the consent form. 1273 
After their review, the study team will discuss the study at length in a phone call/HIPAA compliant 1274 
telecommunication method for consenting that is not face to face. All participants will receive 1275 
verbal explanation in terms suited to their comprehension of the purposes, procedures, and 1276 
potential risks of the study and of their rights as research participants. Extensive discussion of risks 1277 
and possible benefits of participation will be provided. The potential participant will be given an 1278 
opportunity to ask the study team questions or may speak directly with the study physician. The 1279 
potential participant’s understanding of the information presented in the process of consent will be 1280 
assessed by [CONTACT_63290]-ended questions.  1281 
The consent form may be signed electronically for both in- person and telecommunication 1282 
screening visits. Note: For potential participants who are not able to sign an electronic consent [ADDRESS_192733]-2024   Page 57 of 60 
 compliant video conferencing tool (e.g., Zoom, WebEx) will  be utilized during the consenting [ADDRESS_192734] Approval Monitoring (PAM) auditors, representatives of the IRB, or device [ADDRESS_192735] documents and records required to be maintained 1296 
by [CONTACT_093], including but not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) for the 1297 
participants in this study.   1298 
The study participant’s contact [CONTACT_91124] [ADDRESS_192736]-2024   Page 58 of 60 
 Chapter 17:  References  1304 
1. Rogers MAM, Kim C, Banerjee T, Lee JM. Fluctuations in the incidence of type 1 diabetes in the 1305 
[LOCATION_002] from 2001 to 2015: a longitudinal study. BMC medicine. 2017;15(1):199. 1306 
2. Forlenza GP, Rewers M. The epi[INVESTIGATOR_166035] 1 diabetes: what is it telling us? Current opi[INVESTIGATOR_166036] 1307 
endocrinology, diabetes, and obesity. 2011;18(4):248-51. 1308 
3. Committee ADAPP. 6. Glycemic Targets: Standards of Medical Care in Diabetes— 2022. Diabetes 1309 
Care. 2021;45(Supplement_1):S83-S96. 1310 
4. Committee ADAPP. 14. Children and Adolescents: Standards of Medical Care in Diabetes —2022. 1311 
Diabetes Care. 2021;45(Supplement_1):S208-S31. 1312 
5. Malik FS, Sauder KA, Isom S, Reboussin BA, Dabelea D, Lawrence JM, et al. Trends in Glycemic 1313 
Control Among Youth and Young Adults With Diabetes: The SEARCH for Diabetes in Youth Study. 1314 
Diabetes Care. 2022;45(2):285-94. 1315 
6. Sawyer A, Sobczak M, Forlenza GP, Alonso GT. Glycemic Control in Relation to Technology Use in 1316 
a Single Center Cohort of Children With Type 1 Diabetes. Diabetes technology & therapeutics. 2022. [ADDRESS_192737] of intensive treatment of diabetes on the development and progression of long -term 1318 
complications in insulin -dependent diabetes mellitus. The Diabetes Control and Complications Trial 1319 
Research Group. N Engl J Med. 1993;329(14):977-86. [ADDRESS_192738] of glycemic exposure on the risk 1321 
of microvascular complications in the diabetes control and complications trial --revisited. Diabetes. 1322 
2008;57(4):995-1001. [ADDRESS_192739] and EDIC 1324 
studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural 1325 
history. Current diabetes reports. 2010;10(4):276-82. 1326 
10. Jacobson AM, Braffett BH, Cleary PA, Gubitosi- Klug RA, Larkin ME. The long- term effects of type 1327 
1 diabetes treatment and complications on health- related quality of life: a 23 -year follow -up of the 1328 
Diabetes Control and Complications/Epi[INVESTIGATOR_146714] 1329 
cohort. Diabetes Care. 2013;36(10):3131-8. 1330 
11. Nathan DM, Bayless M, Cleary P, Genuth S, Gubitosi -Klug R, Lachin JM, et al. Diabetes control and 1331 
complications trial/epi[INVESTIGATOR_80724] 30 years: 1332 
advances and contributions. Diabetes. 2013;62(12):3976-86. 1333 
12. Nathan DM. The diabetes control and complications trial/epi[INVESTIGATOR_166037] 1334 
complications study at 30 years: overview. Diabetes Care. 2014;37(1):9-16. 1335 
13. Berget C, Messer LH, Forlenza GP. A Clinical Overview of Insulin Pump Therapy for the Management 1336 
of Diabetes: Past, Present, and Future of Intensive Therapy. Diabetes spectrum : a publication of the 1337 
American Diabetes Association. 2019;32(3):194-204. 1338 
14. Forlenza GP, Kushner T, Messer LH, Wadwa RP, Sankaranarayanan S. Factory -Calibrated Continuous 1339 
Glucose Monitoring: How and Why It Works, and the Dangers of Reuse Beyond Approved Duration 1340 
of Wear. Diabetes technology & therapeutics. 2019. 1341 
15. Forlenza GP, Lal RA. Current Status and Emerging Options for Automated Insulin Delivery Systems. 1342 
Diabetes technology & therapeutics. 2022.  [ADDRESS_192740] to artificial pancreas systems revisited: moving downstream. Diabetes Care. 1344 
2015;38(6):1036-43. 1345 
17. Kowalski AJ. Can we really close the loop and how soon? Accelerating the availability of an artificial 1346 
pancreas: a roadmap to better diabetes outcomes. Diabetes technology & therapeutics. 2009;[ADDRESS_192741] 1347 
1:S113-9. 1348 
18. Ware J, Allen JM, Boughton CK, Wilinska ME, Hartnell S, Thankamony A, et al. Randomized Trial 1349 
of Closed- Loop Control in Very Young Children with Type 1 Diabetes. N Engl J Med. 1350 
2022;386(3):209-19. 1351 
19. Brown SA, Kovatchev BP, Raghinaru D, Lum JW, Buckingham BA, Kudva YC, et al. Six- Month 1352 
Randomized, Multicenter Trial of Closed -Loop Control in Type 1 Diabetes. N Engl J Med. 2019. 1353 
20. Breton MD, Kanapka LG, Beck RW, Ekhlaspour L, Forlenza GP, Cengiz E, et al. A Randomized Trial 1354 
of Closed -Loop Control in Children with Type 1 Diabetes. N Engl J Med. 2020;383(9):836-45. [ADDRESS_192742] GM, Fourlanos S, A. Grills C, et al. Closed- Loop Insulin 1356 
Delivery Versus Sensor -Augmented Pump Therapy in Older Adults With Type 1 Diabetes (ORACL): 1357 
A Randomized, Crossover Trial. Diabetes Care. 2021:dc211667. 1358 
22. Collyns OJ, Meier RA, Betts ZL, Chan DSH, Frampton C, Frewen CM, et al. Improved Glycemic 1359 
Outcomes With Medtronic MiniMed Advanced Hybrid Closed- Loop Delivery: Results From a 1360 
Randomized Crossover Trial Comparing Automated Insulin Delivery With Predictive Low Glucose 1361 
Suspend in People With Type 1 Diabetes. Diabetes Care. 2021;44(4):969-75. 1362 
23. McAuley SA, Lee MH, Paldus B, Vogrin S, de Bock MI, Abraham MB, et al. Six Months of Hybrid 1363 
Closed -Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults 1364 
With Type 1 Diabetes: A Randomized, Controlled Trial. Diabetes Care. 2020;43(12):3024-33. 1365 
24. Messer LH, Berget C, Pyle L, Vigers T, Cobry E, Driscoll KA, et al. Real-World Use of a New Hybrid 1366 
Closed Loop Improves Glycemic Control in Youth with Type 1 Diabetes. Diabetes technology & 1367 
therapeutics. 2021. 1368 
25. Da Silva J, Lepore G, Battelino T, Arrieta A, Castañeda J, Grosman B, et al. Real -world Performance 1369 
of the MiniMed ™ 780G System: First Report of Outcomes from 4'120 Users. Diabetes technology & 1370 
therapeutics. 2021. 1371 
26. Breton MD, Kovatchev BP. One Year Real -World Use of the Control -IQ Advanced Hybrid Closed- 1372 
Loop Technology. Diabetes technology & therapeutics. 2021. 1373 
27. Berget C, Akturk HK, Messer LH, Vigers T, Pyle L, Snell -Bergeon J, et al. Real world performance of 1374 
hybrid closed loop in youth, young adults, adults and older adults with type 1 diabetes: Identifying a 1375 
clinical target for hybrid closed loop use. Diabetes, obesity & metabolism. 2021. 1376 
28. Amadou C, Franc S, Benhamou PY, Lablanche S, Huneker E, Charpentier G, et al. Diabeloop DBLG1 1377 
Closed -Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic 1378 
Control in Real -Life Situations Without Serious Adverse Events: 6- Month Follow -up. Diabetes Care. 1379 
2021;44(3):844-6. 1380 
29. Stone MP, Agrawal P, Chen X, Liu M, Shin J, Cordero TL, et al. Retrospective Analysis of 3- Month 1381 
Real-World Glucose Data After the MiniMed 670G System Commercial Launch. Diabetes technology 1382 
& therapeutics. 2018;20(10):689-92. 1383 
30. Forlenza GP, Breton MD, Kovatchev B. Candidate Selection for Hybrid Closed Loop Systems. 1384 
Diabetes technology & therapeutics. 2021.  [ADDRESS_192743]-2024   Page 60 of 60 
 31. Fredette ME, Zonfrillo MR, Park S, Quintos JB, Gruppuso PA, Topor LS. Self -reported insulin pump 1386 
prescribing practices in pediatric type 1 diabetes. Pediatr Diabetes. 2021.  1387 
32. Pauley ME, Berget C, Messer LH, Forlenza GP. Barriers to Uptake of Insulin Technologies and Novel 1388 
Solutions. Med Devices (Auckl). 2021;14:339-54.  1389 